Article Sidebar

Submitted
May 3, 2021
Published
May 3, 2021
Download
PDF
Statistic
Read Counter : 54 Download : 28

Main Article Content

Abstract

Introduction


Dyslipidemia is the most common risk factor for cardiovascular morbidity and mortality worldwide requiring lifelong therapy. Hence cost of drugs plays an important role in patient’s care necessitating the need for all physicians to keep themselves updated regarding latest prices and price variation of various brands of hypolipidemic drugs.


Materials and Methods


Cost of oral hypolipidemic drugs manufactured by different pharmaceutical companies in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” (CIMS) April- July 2017. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets was calculated.


Results


In this study, there exists a wide cost variation among the different brands of same hypolipidemic drug. Percentage cost variation for individual hypolipidemic drugs was found to be highest with atorvastatin (20 mg FC-tablet): 1017.79% followed by rosuvastatin (20mg tablet): 308.16%, gemfibrozil (300mg capsule): 109.14%, lovastatin (20mg tablet): 87.83%, fenofibrate (200mg capsule): 79.53%, simvastatin (5mg tablet): 77.43%, ezetimibe (10mg tablet): 72.84%. Among the fixed dose combination therapy, percentage cost variation was found to be highest with atorvastatin + fenofibrate (10mg + 160mg FC-tablet): 266.67% followed by atorvastatin +ezetimibe (10mg + 10mg tablet): 139.39%, rosuvastatin + fenofibrate (10mg + 160mg tablet): 81.05%


Conclusion


In Indian market, there exists a wide cost variation amongst various brands of oral hypolipidemic drugs of same strength and dosage forms. Therefore, physicians should be encouraged to prescribe the drugs by generic names as they are cheaper and in no way inferior to costlier branded counterpart. This in turn reduces the economic burden on the patients.

Keywords

Cost analysis Cost variation Hypolipidemic drugs

Article Details

How to Cite
Mamatha K.R, & Vishnu K. (2021). Cost variation analysis of various brands of oral hypolipidemic drugs available in Indian pharmaceutical market. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(3), 381-388. https://doi.org/10.61096/ijrpp.v6.iss3.2017.381-388
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Bersot PT. Drug Therapy for Hypercholesterolemia and Dyslipidemia. In:Brunton LL, editor. Goodman and Gilman’s Manual of Pharmacology and Therapeutics. New York: McGraw-Hill; 12, 2010, 884- 891.
  2. [2]. Park K. Epidemiology of chronic non-communicable diseases and conditions. In: Park K, editor. Park’s Textbook of Preventive and Social Medicine. Jabalpur: Bhanot; 23, 2009, 365-372.
  3. [3]. Tripathi KD. Essentials of Medical Pharmacology.New Delhi: Jaypee Brothers Medical Publishers Pvt. Limited; 7, 2013, 634-646.
  4. [4]. Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci 69(1), 2007, 160-3.
  5. [5]. Gupta SK. Proposed Pharmacoeconomics Guidelines for India (PEG-I). IPSOR India.2013, 79:100.
  6. [6]. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med.166(3), 2006, 332-7.
  7. [7]. Current Index of Medical Specialties,2017, 140-147.
  8. [8]. Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st Edition. Himayatnagar, Hyderabad: Orient Longman2004, 72-3.
  9. [9]. Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic ClinPharmacol3, 2014, 954-7.
  10. [10]. Shukla AK, Sharma P. Cost variation analysis of antidyslipidemic drugs. Int J Basic ClinPharmacol5, 2016, 1850-5.
  11. [11]. Kamath L and Satish GR: Cost Variation Analysis of Antihypertensive Drugs Available in Indian Market: An Economic Perspective. Int J Pharm Sci Res 7(5), 2016, 2050-56.doi: 10.13040/IJPSR.0975-8232.7(5).2050-56.
  12. [12]. Zubin S, Apurva D, Vishali L. Pharmacoeconomic study of various brands of antibiotic medication in India. World Journal of Pharmaceutical Research.4(3), 2015, 1600–6.
  13. [13]. Lalan HN, Borde MK, Ray IM. Cost Variation Study of Antidiabetics: Indian Scenario2014, 2013–4.
  14. [14]. Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Outcomes. Circulation.119, 2009, 3028-35.
  15. [15]. World Health Organization. Essential drugs and medicines: Drug finance. Available at: http://www.whoindia.org/EN/Section2/Section/Section160_959.htm. [Last accessed 2017].
  16. [16]. National Pharmaceutical Pricing Authority, Government of India. Available at http://www.nppaindia.nic.in/DPCO2013.pdf.[Last accessed on 2017].